30-year trends in incidence of acute STEMI and NSTEMI in the Belgian Province of Luxembourg. A long-term follow-up of the MONICA-BELLUX registry by Bernhard L. Gerber (10171583)

“…</p><p>b) What this study adds</p><p>In a 30-year registry in Luxembourg using modern AMI definitions, overall, AMI incidence decreased significantly, primarily due to a 3.8-fold reduction in STEMI.…”

Image 4_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

“…The pooled estimates documented a significant decrease in eGFR (CKD-EPI equation) at 6 and 12 months with respect to baseline, using the attributed (female) gender. …”

Image 3_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

“…The pooled estimates documented a significant decrease in eGFR (CKD-EPI equation) at 6 and 12 months with respect to baseline, using the attributed (female) gender. …”

Image 1_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

“…The pooled estimates documented a significant decrease in eGFR (CKD-EPI equation) at 6 and 12 months with respect to baseline, using the attributed (female) gender. …”

Data Sheet 1_TREM-1 as a potential gatekeeper of neuroinflammatory responses: therapeutic validation and mechanistic insights in experimental traumatic brain injury.zip by Yunsheng Zhang (474242)

“…Background<p>Traumatic brain injury (TBI) triggers a cascade of neuroinflammatory responses mediated by microglial activation, which significantly contributes to secondary brain damage. …”

Image 2_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

“…The pooled estimates documented a significant decrease in eGFR (CKD-EPI equation) at 6 and 12 months with respect to baseline, using the attributed (female) gender. …”

Image 5_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

“…The pooled estimates documented a significant decrease in eGFR (CKD-EPI equation) at 6 and 12 months with respect to baseline, using the attributed (female) gender. …”

Data Sheet 1_Burden of falls in China, 1992–2021 and projections to 2030: a systematic analysis for the global burden of disease study 2021.xlsx by Liang Sui (20912441)

“…Joinpoint regression analysis revealed fluctuating trends in prevalence and incidence with periods of increase and decline, and a general decrease in mortality except during brief intervals. …”

Data_Sheet_1_Neuroprotection by upregulation of the major histocompatibility complex class I (MHC I) in SOD1G93A mice.docx by Ana Laura M. R. Tomiyama (16902930)

“…Disease progression upregulated gene transcripts for pro- and anti-inflammatory cytokines, and IFN β treatment significantly decreased mRNA expression for IL4. Overall, the present results demonstrate that a low dosage of IFN β shows therapeutic potential by increasing MHC-I expression, resulting in neuroprotection and immunomodulation.…”

Data Sheet 1_Detection of hemodynamic changes in a porcine lipopolysaccharide model of systemic inflammation using dynamic light scattering measurements of the microcirculation.pdf by Louwrina H. te Nijenhuis (20762678)

“…Both intervention groups showed a Hurst exponent decrease centrally at T2 and peripherally already at T1.…”

Supplementary Material for: Preliminary efficacy, tolerability, and safety analysis of Darolutamide for metastatic castration‑resistant prostate cancer: a single-center, open-label... by Yu J. (3610580)

“…The median time to PSA50 in the Darolutamide group was 1.5 months (95%CI 0.2619- 0.9545), significantly lower than that in the placebo group (3.0 months [95%CI 1.048- 3.818], p= 0.0259); The median time to PSA90 in the experimental group was 4 months (95%CI 0.3094- 1.437), 2 months shorter than that in the placebo group (6.0 months [95%CI 0.6961- 3.232]).With the median follow-up of 6 months, , the median decrease in serum PSA was -81.8% (range -60.4 to -99.9%) in the Darolutamide group and -69.4% (range -50.3 to -89.6%) in the placebo group. …”

Supplementary Material for: Albumin and platelet loss during the application of CytoSorb® in critically ill patients: a post-hoc analysis of the Cyto-SOLVE trial by Brozat C.I. (20130933)

“…However, a significant albumin decrease was observed in those 17 patients with less than 20g albumin substitution during CS therapy (p=0.007, mean 0.17g/dL, 95% CI 0.05 – 0.29). …”

Supplementary tables: Assessing healthcare resource utilization burden and unmet treatment needs in patients with Parkinson’s disease: results from a real-world study by Malgorzata Ciepielewska (22143499)

“…The intermediate versus early group had a significantly greater proportion of patients with unmet treatment needs (p < 0.001), e.g., slowing disease progression, providing neuroprotection. …”

Data Sheet 1_Glucocorticoids and immunoglobulin alone or in combination in the treatment of multisystemic inflammatory syndrome in children: a systematic review and network meta-an... by Junjie Lin (8379594)

“…When compared to combination therapy, GCs monotherapy was associated with a reduction in ICU length of stay [SMD −0.25, 95% CI (−0.85, 0.36)], duration of fever (SMD [−0.42, 95% CI (−0.73, −0.11)], and duration of inotropic support [SMD −0.13, 95% CI (−0.46, 0.20)], as well as a decrease in the incidence of left ventricular (LV) dysfunction [OR 0.96, 95% CI (0.55, 1.68)]. …”

Supplementary data: Assessing healthcare resource utilization burden and unmet treatment needs in patients with Parkinson’s disease: results from a real-world study by Malgorzata Ciepielewska (22143499)

“…The intermediate versus early group had a significantly greater proportion of patients with unmet treatment needs (p < 0.001), e.g., slowing disease progression, providing neuroprotection. …”

Table 1_Has carbon finance been able to promote clean energy development? — a low-carbon technology innovation perspective.xlsx by Rui Cui (622759)

“…It is found that carbon finance significantly promotes clean energy development, but this contribution decreases with the intervention of low-carbon technology innovation. …”

Data Sheet 1_Effectiveness of community-based management models in chronic obstructive pulmonary disease: a systematic review and meta-analysis.docx by Miao Zhan (2625718)

“…Notably, neither approach demonstrated a statistically significant advantage in improving quality of life among COPD populations, as assessed by the St. …”

Effects of Continuous Glucose Monitoring on Impaired Awareness of Hypoglycemia in Older Adults With Type 1 Diabetes: A Post Hoc Analysis of the WISDM Study by Anika Bilal (16701942)

Data Sheet 1_Systemic lipid and glucose modulation differentially affects cognitive function and neuroinflammation in a mouse model of Alzheimer’s disease.xlsx by Demos Kynigopoulos (12420457)

“…Introduction<p>Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by synaptic dysfunction and cognitive decline. …”

Table 1_Carnosine as a protective metabolic mediator in inflammatory lung injury by inhibiting macrophage infiltration and M1-like polarization.docx by Lianjie Ruan (22660265)

“…Multiplex immunofluorescence further demonstrated a significant reduction of macrophage accumulation in the peribronchial regions of the lung following carnosine administration. …”